ViaCyte Revenue and Competitors
Estimated Revenue & Valuation
- ViaCyte's estimated annual revenue is currently $5.3M per year.
- ViaCyte received $80.0M in venture funding in November 2018.
- ViaCyte's estimated revenue per employee is $77,500
- ViaCyte's total funding is $289.5M.
Employee Data
- ViaCyte has 68 Employees.
- ViaCyte grew their employee count by -17% last year.
ViaCyte's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | VP, Head Clinical Development | Reveal Email/Phone |
4 | VP, Regulatory and Quality | Reveal Email/Phone |
5 | VP, IP Counsel & Diversity & Inclusion Officer | Reveal Email/Phone |
6 | General Counsel | Reveal Email/Phone |
7 | Senior Director, Manufacturing | Reveal Email/Phone |
8 | Chief Technology Officer | Reveal Email/Phone |
9 | Chief Scientific Officer | Reveal Email/Phone |
10 | Sr. Director, Human Resources | Reveal Email/Phone |
ViaCyte Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $318.9M | 1571 | N/A | N/A | N/A |
#2 | $7.4M | 48 | -2% | N/A | N/A |
What Is ViaCyte?
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications. ViaCyte has two products in clinical development. The first is called the PEC-Direct product candidate, which delivers proprietary pancreatic progenitor cells (PEC-01 cells) in a non-immunoprotective device. The PEC-Direct product candidate is being developed for type 1 diabetes (T1D) patients who have hypoglycemia unawareness, recurrent severe hypoglycemic episodes, and/or extreme glycemic lability. The second product is called the PEC-Encap (also known as VC-01) product candidate. The PEC-Encap product candidate delivers pancreatic progenitor cells in an immunoprotective device and is being developed as a potential therapy for all diabetes patients who use insulin to control their disease. www.viacyte.com
keywords:Biotechnology,Healthcare,Pharmaceuticals
$289.5M
Total Funding
68
Number of Employees
$5.3M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ViaCyte News
ViaCyte is a clinical-stage cellular therapy company with an advanced stem cell platform that delivers therapeutic proteins to restore health in...
Paul Laikind, PhD, was CEO of ViaCyte from 2012 until 2020, where he lead the development of the first stem cell-derived cell therapies...
Other global companies are also working to cure diabetes, such as ViaCyte, CRISPR, and Novo Nordisk, one of the biggest insulin...
ViaCyte, a clinical stage biotech company, has raised $115 million in Series D financing, to bring forward two phase 2 studies of type 1 diabetes candidates. Michael Yang, President and CEO, ViaCyte The round includes participation from existing investors Bain Capital Life Sciences, TPG Capital ...
ViaCyte, a San Diego CA-based regenerative medicine company, raised $45M in Series D funding. The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Cap ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.5M | 68 | 21% | N/A |
#2 | $7.3M | 68 | 15% | N/A |
#3 | $12.9M | 68 | 36% | N/A |
#4 | $17.1M | 68 | -12% | N/A |
#5 | $13.5M | 68 | 24% | N/A |
ViaCyte Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2001-10-04 | $7.0M | B | Article | |
| 2001-12-19 | $4.0M | Strategic Investmen | SurModics | Article |
| 2003-05-05 | $Undisclosed | D | Multiple | Article |
| 2007-07-17 | $25.0M | C | Johnson and Johnson Developmen | Article |
| 2013-07-11 | $10.6M | Undisclosed | Article | |
| 2014-02-07 | $7.0M | Undisclosed | JDRF | Article |
| 2014-08-11 | $5.4M | C-1 | Article | |
| 2014-08-26 | $20.0M | Undisclosed | Janssen Research & Development LLC | Article |
| 2017-05-23 | $10.0M | Undisclosed | Asset Management Partners, | Article |
| 2018-11-30 | $80.0M | D | Bain Capital Life Sciences | Article |